Geographic Atrophy

Latest News

Ocugen completes dosing in phase 2 ArMaDa clinical trial - Image credit: Adobe Stock / ©nobeastsofierce
Ocugen, Inc. completes dosing in Phase 2 portion of ArMaDa clinical trial for OCU410

March 12th 2025

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

Woman in scrubs holding a pill and glass of water Image credit: AdobeStock/NewAfrica
Cognition Therapeutics announces manuscript publication on oral drug candidate zervimesine (CT1812) for treatment of dry AMD

February 28th 2025

optos MonacoPro captures retinal images in a patient with myopia - Image credit: Optos
Optos ushers in new generation of imaging with MonacoPro ultra-widefield and OCT

February 19th 2025

FDA approved amended label for avacincaptad pegol (Izervay) - Image credit: Adobe Stock / ©Araki Illustrations
FDA approves amended label for Izervay for geographic atrophy

February 13th 2025

woman with geographic atrophy participates in preclinical trial to reduce retinal cell death via ophthalmic topical gel - Image credit: Adobe Stock / ©K Davis/peopleimages.com
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel

February 6th 2025

Video Series
Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.